Send me real-time posts from this site at my email
Zacks

Abbott (ABT) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Abbott (ABT) closed at $83.42, marking a +1.67% move from the previous day. This change outpaced the S&P 500's 0.97% gain on the day. At the same time, the Dow added 1.35%, and the tech-heavy Nasdaq gained 1.39%.

Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had gained 8.29% over the past month. This has outpaced the Medical sector's gain of 3.17% and the S&P 500's gain of 0.64% in that time.

Investors will be hoping for strength from ABT as it approaches its next earnings release. On that day, ABT is projected to report earnings of $0.80 per share, which would represent year-over-year growth of 9.59%. Meanwhile, our latest consensus estimate is calling for revenue of $7.99 billion, up 2.82% from the prior-year quarter.

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.22 per share and revenue of $31.92 billion. These totals would mark changes of +11.81% and +4.4%, respectively, from last year.

Any recent changes to analyst estimates for ABT should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. ABT is currently sporting a Zacks Rank of #3 (Hold).

Digging into valuation, ABT currently has a Forward P/E ratio of 25.51. This represents a no noticeable deviation compared to its industry's average Forward P/E of 25.51.

Also, we should mention that ABT has a PEG ratio of 2.31. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Products industry currently had an average PEG ratio of 2.39 as of yesterday's close.

The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 84, which puts it in the top 33% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow ABT in the coming trading sessions, be sure to utilize Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Abbott Laboratories (ABT): Free Stock Analysis Report
 
To read this article on Zacks.com click here.

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue